Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.71 |
| ▸ | IDO1 | P14902 | 16/20 | 0.63 |
| ▸ | NOS3 | P29474 | 1/20 | 0.63 |
| ▸ | NOS2 | P35228 | 1/20 | 0.63 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5900169 | 0.98 | NOS1 (0.68) | NOS1IDO1NOS3NOS2SLC11A2 | |
| Hydrochloric Acid SCHEMBL6867456 | 0.98 | NOS1 (0.68) | NOS1IDO1NOS3NOS2SLC11A2 | |
| SCHEMBL5450413 | 0.84 | NOS1 (1.00) | NOS1IDO1NOS3NOS2SLC11A2 | |
| SCHEMBL17342524 | 0.82 | ALDH1A1 (0.79) | NOS1IDO1NOS3NOS2ALDH1A1 | |
| SCHEMBL28155965 | 0.81 | ALDH1A1 (0.52) | NOS1IDO1NOS3NOS2ALDH1A1 | |
| SCHEMBL15457403 | 0.78 | ALDH1A1 (0.54) | NOS1IDO1NOS3NOS2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11186538 | 0.77 | IDO1 (0.65) | NOS1IDO1NOS3NOS2SLC11A2 | |
| Hydrochloric Acid SCHEMBL1770359 | 0.77 | IDO1 (0.65) | NOS1IDO1NOS3NOS2SLC11A2 | |
| SCHEMBL18197946 | 0.77 | SLC11A2 (0.58) | NOS1IDO1NOS3NOS2SLC11A2 | |
| Benzyl Carbamimidothioate SCHEMBL974745 | 0.77 | IDO1 (1.00) | NOS1IDO1NOS3NOS2SLC11A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656953-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656953-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-05-23 | — | — | US | disclosed |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-07 | — | — | US | disclosed |
| US-8642278-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642278-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2010030810-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030810-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030811-A2 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030811-A2 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-01 | — | — | US | disclosed |
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-01 | — | — | US | disclosed |
| WO-2007062222-A2 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1056771-B1 | STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2005-11-30 | — | — | EP | disclosed |
| EP-1056771-A1 | STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043699-A1 | STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | MGAM, MGAM2, B2M | NOS1 3314/4885IDO1 2104/4885NOS3 3952/4885 |
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | RB1, RAF1, NRAS | NOS1 3526/4885IDO1 4187/4885NOS3 3705/4885 |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | RB1, RAF1, NRAS | NOS1 3526/4885IDO1 4187/4885NOS3 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.